Generic products to be the growth
factor for bleeding disorders treatment market
The Bleeding
Disorder Treatment Market is driven by the large customer base, growing
awareness about the bleeding disorders and available cures, and favorable
compensation policies. Patent expiry of existing brands will also provide
generic drug manufacturers opportunities to enter the lucrative bleeding
disorder therapeutics market. Market for bleeding disorder treatment is mostly
focused towards western countries of North America and Europe, owing to the
high price of branded drugs. Low cost drugs will help in market penetration in
under developed and developing countries, where patients cannot afford high
cost of medical treatment. Hence,
availability of cheap generic drugs will boost market growth in the countries
of Middle East and Africa, Asia-Pacific (APAC), and Latin America.
North America is estimated to
contribute the largest share of the market throughout the forecast period. The
market in APAC is estimated to register the highest growth during the forecast
period, owing to increasing awareness of these disorders in the emerging
economies such as India and China.
The global bleeding disorder
treatment market is highly competitive in nature. Technological advances will
expand the boundaries of the market by adding new products such as Shire launched Vonvendi in the U.S. (In 2016),
bringing the first recombinant von Willebrand factor treatment to market eight
months after winning approval from the Food and Drug Administration(FDA). Key
players operating in the global bleeding disorders treatment market are Bayer
Healthcare, Biogen Idec, Novo Nordisk, Xenetic Biosciences, Shire, Sanofi,
Cangene Corporation, CSL Behring, Alnylam Pharmaceuticals, Pfizer, Inc., Novo
Nordisk, Amgen, Inc., Janssen Pharmaceuticals, and Octapharma.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/527
A bleeding disorder is a state in
which the normal clotting function of blood is adversely affected. On an injury
to the body, blood normally starts to clot to prevent major loss of blood.
Occasionally, certain situations prevent blood from clotting properly, which
can result in heavy or prolonged bleeding. Bleeding disorders can cause
abnormal bleeding both outside and inside of the body. Some disorders can
drastically increase the amount of blood lost by the body. Others cause
bleeding to follow under the skin or in vigorous organs, such as the brain.
Normal blood clotting involves blood components called ‘platelets’ and as many
as there are 20 different plasma proteins in body called as blood clotting or
coagulation factors. These factors interact with other chemicals to form a
substance called fibrin which stops bleeding. Complications can occur when
certain factors are low or missing in body. Bleeding problems can range from
mild to severe. Some bleeding disorders are present at time of birth and some
are passed through families (inherited).
According to American Society of
Hematology, in 2016, around 20,000 people in the U.S. suffer from hemophilia, a
condition that is predominantly observed in males. Hemophilia is the most well-known inherited
bleeding disorder, although it is rather rare. On the other hand, many people
are affected by von Willebrand disease, the most common inherited bleeding
disorder in the U.S. caused by clotting proteins. This disease can affect both
males and females and is found in nearly 1% of the U.S. population. And
according to the Centers for Disease Control and Prevention (CDC) statistics,
in the U.S. around 400 newborns suffer from hemophilia every year.
Key Developments:
In February 2020, Novo Nordisk
A/S launched Esperoct, an anti-hemophilic factor in U.S. for the treatment of
adults and children with hemophilia A i.e., to reduce as well as control the
bleeding episodes even during surgery.
In December 2019, Johnson and
Johnson in collaboration with Spanish multinational, Grifols, produced
Vistaseal biological sealant, which is a blood stopping protein spray and is
designed to quickly seal and control bleeding during complicated surgeries
where suturing, ligature or cauterization cannot be applied. The spray consist
of two clotting, human fibrinogen and thrombin, which helps in the sealing of
the wound.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/bleeding-disorders-treatment-market-527
In 2018, on the occasion of 70th
anniversary of National Hemophilia Foundation (NHF), a Red Tie Campaign was
launched in order to create awareness about the bleeding disorders. The main
aim of the campaign was to increase the accessibility of the quality healthcare
to the patient suffering from bleeding disorders by providing them health
insurance with life time benefits.
In 2018, European Association for
Hemophilia and Allied Disorders formed a working group on women and bleeding
disorders after receiving the approval for the proposal. The aim of the working
group is to educate the healthcare providers and understand the needs of the
women with bleeding disorders.
In 2017, LFB Biopharmaceuticals
launched FibCLOT, the human fibrinogen concentrate. FibCLOT is effective in
patients with congenital hypo- or afibrinogenaemia and who have high tendency
to bleed.
In 2017, Pfizer launched
Hemocraft, a modification of the video game Minecraft, especially for children
who are 8-16 years old. The game educates the children about the importance of
integrating treatment in their daily lives.
In 2017, another modification by
Pfizer involves the development of HemMobile Striiv Wearable wrist band, for
the patients suffering from hemophilia. The device helps to track daily
activity levels and also monitors heart rate. The device integrates with the
Pfizer’s existing HemMobile app, which helps people to monitor their bleeding
episodes.
In June 2016, a scientist working
at Kingston Health Sciences Center (KGHRI) launched a website “Let’s Talk
Period”, where the women need fill the “self- administered bleeding assessment”
(Self – BAT) form in order to diagnose whether they are suffering from bleeding
disorders or not. The website also directs the women to the referral centers
where they can consult with the respective doctors for the effective treatment.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/527
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment